½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1493247

¼¼°èÀÇ DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå - ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¿ëµµº°, Áö¿ªº° ºÎ¹® ¿¹Ãø(2024-2030³â)

DNases, Ligases, And RNA Polymerases Market Size, Share & Trends Analysis Report By Application (DNases-Biopharmaceutical Processing, Ligases- ligonucleotide Synthesis), By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è DNAse, ¸®°¡¾ÆÁ¦ ¹× RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 16¾ï 2,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2024³âºÎÅÍ 2030³â±îÁöÀÇ CAGRÀº 10.63%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù. R&D ºñ¿ë Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. °Ô´Ù°¡, DNA °ü·Ã ±â¼ú Çõ½Å¿¡ ´ëÇÑ ÁÖ¸ñ°ú ÇÔ²², ¹ÙÀÌ¿À ÀǾàÇ° »ý»êÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °Íµµ ¿¹Ãø ±â°£ µ¿¾È ¼¼°è DNAse ½ÃÀåÀÇ ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹¸¦ µé¾î, 2020³â 6¿ù Alphazyme°ú Codexis´Â Áø´Ü ¹× ¿¬±¸¸¦ À§ÇÑ »õ·Î¿î È¿¼Ò¸¦ Á¦°øÇϱâ À§ÇÑ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ü°áÇß½À´Ï´Ù. DNase´Â ´Ù¾çÇÑ ¸¸¼º Áúȯ ¹× ¼ÒÈ­±â°è ÁúȯÀÇ Ä¡·á¿¡ ÇʼöÀûÀÎ ÀǾàÇ° °ü·Ã DNA È¿¼ÒÀÇ Ã¤¿ë Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇØ ÃÖ±Ù¿¡ Å« ½ÃÀå Á¡À¯À²À» ȹµæÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯Àü°øÇаú ´Ü¹éÁú°øÇÐ µµÀÔ µî »ý¸í°øÇаú ÀǾàÇ° ºÐ¾ßÀÇ ¹ßÀüÀÌ È¿¼ÒÀÇ ¿ëµµ È®´ë¿¡ µµ¿òÀÌ µÇ°í ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ °¡Á®¿Ã °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

¸®°¡¾ÆÁ¦¸¦ ¾Ï Ä¡·áÀÇ Ç¥ÀûÀ¸·Î °³¹ßÇϱâ À§ÇÑ ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡´Â ¿¹Ãø±â°£¿¡ À־ ÀÌ ºÐ¾ß¸¦ °ßÀÎÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä Á¦Á¶¾÷üÀÇ Àü·«Àû È°µ¿Àº ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ °¡Á®¿Ã °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ±âŸ ÇコÄɾî Áøº¸, ÀÇÇС¤»ý¸í°úÇÐ ºÐ¾ßÀÇ ±Ù´ëÈ­ ¼ö¿ä Áõ°¡, °Ô³ð ±â¼ú °³¹ßÀ» À§ÇÑ Á¤ºÎ ÅõÀÚ Áõ°¡, ¹Î°£¡¤°øÀû ¿¬±¸È¸»ç¿¡ ÀÇÇÑ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ¼ö¿ä ±ÞÁõ µîÀÌ ÀÌ ºÐ¾ßÀÇ ¼ºÀå À» ¹Ð¾î ¿Ã¸®´Â ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀÇ »óȲÀº RNA Æú¸®¸Þ¶óÁ¦ÀÇ Àû¿ë¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÇöÀç »ý»ê °øÁ¤¿¡¼­ mRNA¸¦ »ç¿ëÇϰųª mRNA ºÐÀÚ¸¦ ±â¹ÝÀ¸·Î ÇÏ´Â ¹é½Å°ú Ä¡·áÁ¦°¡ 150À¯Çü ÀÌ»ó ÀÖ¾î Æø³ÐÀº ÀûÀÀÁõ Ä¡·á¹ýÀ¸·Î Æò°¡µÇ°í ÀÖ½À´Ï´Ù. mRNA ¹é½ÅÀÇ ´ëºÎºÐÀº ¼¼°è °¢±¹¿¡¼­ ºñ»ó¿ëÀ¸·Î ½ÂÀεǾú½À´Ï´Ù.

¿¹¸¦ µé¾î, ModernnaÀÇ mRNA-1273°ú BioNTech/PfizerÀÇ BNT-162 ¹é½ÅÀº ¼¼°è ¿©·¯ Áö¿ª¿¡¼­ »ç¿ëÀÌ ½ÂÀεǾú½À´Ï´Ù. ¶ÇÇÑ mRNA ¹é½Å °³¹ßÀ» À§ÇØ ¸·´ëÇÑ ÀÚº» ÅõÀÚ°¡ ÀÌ·ç¾îÁö°í ÀÖ´Â ¿¹µµ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 6¿ù, Sanofi´Â mRNA ¹é½Å °³¹ß ¼¾ÅÍ¿¡ ¿¬°£ ¾à 452.12´Þ·¯ÀÇ ÅõÀÚ¸¦ ¼±¾ðÇß½À´Ï´Ù.

DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®:

  • DNAase ¿ëµµº°·Î DNA ±â¹Ý ¿¬±¸ Áõ°¡, ¿¬±¸ ÀÚ±Ý Áõ°¡, DNaseÀÇ ½Å·Ú¼º ÀÖ´Â À¯¿ë¼ºÀ¸·Î ÀÎÇØ 2023³â¿¡´Â ´Ù¸¥ ÀÀ¿ë ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
  • ¸®°¡¾ÆÁ¦ ¿ëµµº°·Î´Â ´Ù¸¥ ¿ëµµ ºÐ¾ß°¡ 2023³â¿¡ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. À¯ÀüÀÚ Ä¡·á¿¡¼­ ¸®°¡¾ÆÁ¦ »ç¿ë Áõ°¡¿Í DNA ½ÃÄö½ÌÀÇ ¼ºÀå°ú °°Àº ƯÁ¤ ¿äÀÎÀÌ ¿¹Ãø ±â°£ µ¿¾È ºÎ¹® ¼ºÀå¿¡ Å« ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
  • RNA Æú¸®¸Þ¶óÁ¦ÀÇ Àû¿ë¿¡ µû¶ó COVID-19 ¹× ¿¬±¸ È°µ¿À» À§ÇÑ mRNA ±â¹Ý ¹é½Å ¼ö¿ä Áõ°¡·Î ÀÎÇØ mRNA »ý»êÀÌ 2023³â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ¿¹¸¦ µé¾î, Modernna´Â 3°³ÀÇ ½Å±Ô °³¹ß ÇÁ·Î±×·¥À¸·Î mRNA ¹é½Å ÆÄÀÌÇÁ¶óÀÎÀ» È®´ëÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ÀÌ ÇÁ·Î±×·¥Àº ¼öµÎ ¹× ´ë»ó Æ÷Áø ¹ÙÀÌ·¯½º(VSV), ´Ü¼ø Ç츣Æ佺 ¹ÙÀÌ·¯½º(HSV) ¹× ½Å±Ô üũ Æ÷ÀÎÆ® ¾Ï ¹é½ÅÀ» ´ë»óÀ¸·ÎÇÕ´Ï´Ù.
  • ºÏ¹Ì´Â À¯ÀüÀÚ Ä¡·á ¼ö¿ä Áõ°¡, À¯Àü Áúȯ ¹× ¾Ï Áõ°¡, ¿¬±¸ ±â°üÀÇ Á¸Àç, ½Å±Ô À¯ÀüÀÚ Ä¡·á ¿¬±¸¸¦ À§ÇÑ ¿¬±¸ºñ Áõ°¡, COVID-19ÀÇ DNA ±â¹Ý ¹é½Å Á¦Á¶ ¼ö¿ä Áõ°¡·Î 2023³â ¼¼°è ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, À¯ÀüÀÚ Ä¡·á ¼ö¿ä Áõ°¡, Àα¸¹Ðµµ Áõ°¡·Î ÇâÈÄ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå °ßÀÎ ¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå ºÐ¼® µµ±¸
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå : DNase ¿ëµµÀÇ ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Dnase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå Dnase ¿ëµµÀÇ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ Dnase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м® : Dnase ¿ëµµº°(2018-2030³â)
  • ¹ÙÀÌ¿À ÀǾàÇ° ó¸®
  • ±âŸ ¿ëµµ

Á¦5Àå DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå : ¸®°¡¾ÆÁ¦ÀÇ ¿ëµµ ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ Dnase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå ¸®°¡¾ÆÁ¦ÀÇ ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ Dnase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м® : ¸®°¡¾ÆÁ¦ ¿ëµµº°(2018-2030³â)
  • ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º
  • ±âŸ ¿ëµµ

Á¦6Àå DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå : RNA Æú¸®¸Þ¶óÁ¦ÀÇ ¿ëµµ ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°è DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå RNA Æú¸®¸Þ¶óÁ¦ÀÇ ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°è Dnase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м® : RNA Æú¸®¸Þ¶óÁ¦ ¿ëµµº°, 2018³âºÎÅÍ 2030³â
  • mRNA »ý»ê
  • ±âŸ ¿ëµµ

Á¦7Àå DNase, ¸®°¡¾ÆÁ¦, RNA Æú¸®¸Þ¶óÁ¦ ½ÃÀå : Áö¿ªÀÇ ÃßÁ¤ ¹× µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®(2018-2030³â):
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîƼ³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ±â¾÷/°æÀïÀÇ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷½ÃÀå Æ÷Áö¼Å´× ºÐ¼®, 2023³â
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ/»óÀå ±â¾÷
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Agilent Technologies, Inc.
    • Promega Corporation
    • New England Biolabs
    • RayBiotech, Inc.
    • BioVision, Inc.
    • ABclonal, Inc.
    • QIAGEN NV
    • Takara Bio, Inc.
    • Abnova Corporation.
    • Calzyme
    • ArcticZymes Technologies
    • Worthington Biochemical Corporation
    • MBL International
    • MyBioSource
    • BPS Bioscience Inc.
    • Sino Biological
    • Novus Biologicals
JHS 24.06.20

DNases, Ligases, And RNA Polymerases Market Growth & Trends:

The global DNases, ligases, and RNA polymerases market size is expected to reach USD 1.62 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 10.63% from 2024 to 2030. Increasing research and development expenditure is one of the key factors fueling market growth. Furthermore, rising biopharmaceutical production along with a focus on DNA-related innovations is expected to positively impact the global DNases market growth over the forecast period.

For instance, in June 2020, Alphazyme and Codexis entered into a strategic partnership to provide novel enzymes for diagnostics and research. DNases have continued to garner a significant market share in recent years owing to factors such as an increase in the adoption of DNA enzymes related to pharmaceuticals, which are essential for the treatment of various chronic disorders and digestive diseases. In addition, developments in the biotechnology and pharmaceutical fields, such as the introduction of genetic and protein engineering, have helped in expanding applications of enzymes, which is expected to offer lucrative growth opportunities in the forecast period.

An increase in R&D investments to develop ligases as the target for therapeutic applications in cancer is estimated to drive the segment in the forecast period. In addition, strategic activities by major manufacturers will offer lucrative growth opportunities in the projected period. Other factors augmenting segment growth include advancements in healthcare, increasing demand for modernization in the field of medical academics and life sciences, growing investments by governments to develop genomic technologies, and a surge in the demand for oligonucleotide synthesis by private and public research firms.

The COVID-19 pandemic situation has offered lucrative opportunities for RNA polymerase applications. Currently, there are over 150 vaccines and therapeutics that either use mRNA in their production processes or are based on mRNA molecules, which are being assessed for the treatment of a wide range of indications. Many mRNA vaccines are approved for emergency use in many countries across the globe.

For instance, Moderna's mRNA-1273 and BioNTech/ Pfizer BNT-162 vaccines have been approved for use across various regions globally. Moreover, there are instances of huge capital investments for the development of mRNA vaccines. For instance, in June 2021, Sanofi declared an investment of around USD 452.12 annually for its mRNA vaccines development center.

DNases, Ligases, And RNA Polymerases Market Report Highlights:

  • By DNAse application, the other applications segment dominated the market in 2023 due to a rise in DNA-based research, an increase in research funding, and reliable utility of DNase in applications
  • By ligase application, the other applications segment held the maximum share in 2023. Certain factors such as the rising use of ligases in gene therapies and growth in DNA sequencing are expected to play a major role in the segment growth during the forecast period
  • By RNA polymerases application, mRNA production dominated the market in 2023 due to increasing demand for mRNA-based vaccines for COVID-19 and research activities. For instance, Moderna is set to expand its mRNA vaccine pipeline with three new development programs. The programs will target the varicella-zoster virus (VSV), herpes simplex virus (HSV), and a novel checkpoint cancer vaccine
  • North America dominated the global market in 2023 owing to increasing demand for gene therapy, rise in the number of genetic disorders and cancer, the presence of research institutes, rising research funding for research on novel gene therapy, and rise in the demand for DNA-based vaccine production for COVID-19
  • Asia Pacific is expected to grow considerably in the future owing to the rising prevalence of genetic disorders, rising demand for gene therapy, and high population density

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. DNases Application
    • 1.2.2. Ligases Application
    • 1.2.3. RNA Polymerases Application
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. DNases, Ligases, And RNA Polymerases Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing academic and industrial interest in mRNA technology
      • 3.2.1.2. Advancements in biotechnology and molecular biology
      • 3.2.1.3. Increasing demand for gene therapy
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory challenges related to DNases, ligases, And RNA polymerases
  • 3.3. DNases, Ligases, And RNA Polymerases Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. DNases, Ligases, And RNA Polymerases Market: DNases Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global DNases, Ligases, And RNA Polymerases Market DNases Application Movement Analysis
  • 4.3. Global DNases, Ligases, And RNA Polymerases Market Size & Trend Analysis, by DNases Application, 2018 to 2030 (USD Million)
  • 4.4. Biopharmaceutical Processing
    • 4.4.1. Biopharmaceutical processing market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Other Applications
    • 4.5.1. Other applications market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. DNases, Ligases, And RNA Polymerases Market: Ligases Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global DNases, Ligases, And RNA Polymerases Market Ligases Application Movement Analysis
  • 5.3. Global DNases, Ligases, And RNA Polymerases Market Size & Trend Analysis, by Ligases Application, 2018 to 2030 (USD Million)
  • 5.4. Oligonucleotide Sysnthesis
    • 5.4.1. Oligonucleotide synthesis market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Other Applications
    • 5.5.1. Other applications methylation market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. DNases, Ligases, And RNA Polymerases Market: RNA Polymerases Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global DNases, Ligases, And RNA Polymerases Market RNA Polymerases Application Movement Analysis
  • 6.3. Global DNases, Ligases, And RNA Polymerases Market Size & Trend Analysis, by RNA Polymerases Application, 2018 to 2030 (USD Million)
  • 6.4. mRNA Production
    • 6.4.1. mRNA production market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Other Applications
    • 6.5.1. Other applications market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. DNases, Ligases, And RNA Polymerases Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Norway
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Regulatory framework
      • 7.5.8.3. Competitive scenario
      • 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Mexico
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Thermo Fisher Scientific, Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Merck KGaA
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Agilent Technologies, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Promega Corporation
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. New England Biolabs
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. RayBiotech, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. BioVision, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. ABclonal, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. QIAGEN N.V.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Takara Bio, Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Abnova Corporation.
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Calzyme
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Product benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. ArcticZymes Technologies
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Product benchmarking
      • 8.4.13.4. Strategic initiatives
    • 8.4.14. Worthington Biochemical Corporation
      • 8.4.14.1. Company overview
      • 8.4.14.2. Financial performance
      • 8.4.14.3. Product benchmarking
      • 8.4.14.4. Strategic initiatives
    • 8.4.15. MBL International
      • 8.4.15.1. Company overview
      • 8.4.15.2. Financial performance
      • 8.4.15.3. Product benchmarking
      • 8.4.15.4. Strategic initiatives
    • 8.4.16. MyBioSource
      • 8.4.16.1. Company overview
      • 8.4.16.2. Financial performance
      • 8.4.16.3. Product benchmarking
      • 8.4.16.4. Strategic initiatives
    • 8.4.17. BPS Bioscience Inc.
      • 8.4.17.1. Company overview
      • 8.4.17.2. Financial performance
      • 8.4.17.3. Product benchmarking
      • 8.4.17.4. Strategic initiatives
    • 8.4.18. Sino Biological
      • 8.4.18.1. Company overview
      • 8.4.18.2. Financial performance
      • 8.4.18.3. Product benchmarking
      • 8.4.18.4. Strategic initiatives
    • 8.4.19. Novus Biologicals
      • 8.4.19.1. Company overview
      • 8.4.19.2. Financial performance
      • 8.4.19.3. Product benchmarking
      • 8.4.19.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦